(Q24234493)

2

0 references

Peter Black

4

object named as

Peter N Black

0 references

author name string

Jimmy Chong

1

0 references

Bonnie Leung

Cochrane Database of Systematic Reviews

3

0 references

publication date

11 May 2011

0 references

published in

0 references

cites work

Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

COPD, a multicomponent disease: implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Theophylline: new perspectives for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Theophylline in chronic obstructive pulmonary disease: new horizons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Phosphodiesterase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Minimal clinically important differences in COPD lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Cyclic nucleotide phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

PDE4 inhibitors in COPD--a more selective approach to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

Chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

inferred from DOI database lookup

7 January 2021

based on heuristic

St. George's Respiratory Questionnaire: MCID

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3

inferred from DOI database lookup

7 January 2021

based on heuristic

Left atrial dysfunction in patients with atrial fibrillation after successful rhythm control for > 3 months

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002309.PUB3